8 Nov 2017 07:00
November 8, 2017
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 53,015 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to the exercise of options and warrants (the "Issuance").
The 53,015 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on November 14, 2017.
Total Voting Rights
Following the Issuance, the issued share capital of the Company will consist of 151,528,331 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,485,414. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact
Verseon Corporation | www.verseon.com |
Tina Schlafly | +1 (510) 225 9000 |
| |
Cenkos Securities (NOMAD and Joint Broker) |
|
Neil McDonald / Beth McKiernan | +44 (0) 20 7397 8900 |
| |
Cantor Fitzgerald Europe (Joint Broker) |
|
Marc Milmo / Phil Davies / Callum Butterfield | +44 (0) 20 7894 7000 |
Mirabaud Securities LLP (Joint Broker) | |
Peter Krens | +44 (0) 20 7321 2508 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) |
|
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts |
|
Simon Vane Percy | +44 (0) 1737 821 890 |